Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

NCT01003184 · Completed

Last updated 2026-05-28

This clinical trial tested whether once-weekly exenatide helps adults with type 2 diabetes better control their blood sugar and lose weight compared to daily or twice-daily insulin detemir over 26 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 222 people

Who can join Ages 18+ · all sexes

Timeline Started 2009-10 · est. completion 2011-12

Where 34 sites · Ireland, United Kingdom

What this study is testing ClinicalTrials.gov NCT01003184 ↗

Description as written by the study sponsor.

The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.

Treatments tested

exenatide once weekly Drug

subcutaneous injection, 2mg, once a week
insulin detemir also known as Levemir Drug

subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day

Main thing measured	Percentage of Patients Achieving Glycosylated Hemoglobin (HbA1c) Concentration ≤7.0% With Weight Loss (≥1.0 kg) at Endpoint (Week 26)
Sponsor	AstraZeneca
Conditions studied	Type 2 Diabetes Mellitus
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01003184 ↗